D
David H. Johnson
Researcher at Northwestern University
Publications - 4
Citations - 1762
David H. Johnson is an academic researcher from Northwestern University. The author has contributed to research in topics: Chemotherapy & Etoposide. The author has an hindex of 2, co-authored 4 publications receiving 1668 citations. Previous affiliations of David H. Johnson include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
Gregory A. Curt,William Breitbart,David Cella,Jerome E. Groopman,Sandra J. Horning,Loretta M. Itri,David H. Johnson,Christine Miaskowski,Susan L. Scherr,Russell K. Portenoy,Nicholas J. Vogelzang +10 more
TL;DR: Cancer-related fatigue is common among cancer patients who have received chemotherapy and results in substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers.
Journal ArticleDOI
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
Philip Bonomi,KyungMann Kim,Diane Fairclough,David Cella,John W. Kugler,Eric K. Rowinsky,Michael Jiroutek,David H. Johnson +7 more
TL;DR: Paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplarin as the reference regimen in the recently completed phase III trial of paclitaxels in advanced non-small-cell lung cancer.
Early C hange i n P atient-Reported H ealth D uring L ung C ancer Chemotherapy P redicts C linical O utcomes B eyond T hose Predicted b y B aseline R eport: R esults F rom E astern Cooperative O ncology G roup S tudy 5 592
TL;DR: In this paper, the ability of longitudinal patientreported health (PRH) scores to enhance prediction of clinical outcomes beyond baseline scores was evaluated using regression analyses, and the predictive ability of the five subscales of the Functional Assessment of Cancer Therapy-Lung (physical, functional, social/family, emotional well-being and the lung cancer subscale) as well as the trial outcome index (TOI) aggregate score.
Comparison o f S urvival a nd Q uality o f L ife i n A dvanced Non-Small-Cell L ung C ancer P atients T reated W ith T wo Dose L evels o f P aclitaxel C ombined W ith C isplatin V ersus Etoposide W ith C isplatin: R esults o f a n E astern Cooperative O ncology G roup T rial
Philip Bonomi,KyungMann Kim,Diane Fairclough,David Cella,John W. Kugler,Eric K. Rowinsky,Michael Jiroutek,David H. Johnson +7 more
TL;DR: In this paper, the authors conducted a randomized trial comparing paclitaxel and cisplatin-based chemotherapy to a standard chemotherapy regimen consisting of cis-platin and etoposide.